Jimenez PL, et al. - In this descriptive retrospective, study, researchers assessed the outcome of secukinumab vs ustekinumab for skin clearance in subjects with moderate-to-severe psoriasis following one year of treatment. At week 52, they noted a higher percentage of patients reached a psoriasis area and severity index (PASI) 75 response and higher whitening rates in the secukinumab treatment group vs the ustekinumab treatment group. They observed better PASI 75 response rates in the secukinumab group vs the ustekinumab group after 52 weeks in biologic-naive cases and among those earlier treated with one line or with two or more previous biologic lines. They also noted that these difference were greater in the number of subjects reaching a PASI 90 response in the secukinumab group vs the ustekinumab group in biologic-naive cases and in those previously treated with one or with two or more treatment lines.